Incretin Atlas › Trials › TRIUMPH-4 / TRIUMPH-1-OA
TRIUMPH-4 / TRIUMPH-1-OA
Retatrutide · Knee osteoarthritis + obesity
Design
- Molecule(s)
- Retatrutide
- Population
- Knee osteoarthritis + obesity
- Official title
- A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Registry status
- completed · 2023-08 → 2025-11
- Participants
- 1019
- Duration
- 68 weeks
- Registry
- NCT05929066, NCT05931367
Outcomes in the indication
TRIUMPH-4 / TRIUMPH-1-OA Retatrutide · Knee osteoarthritis + obesity · 68 weeks · n = 1019 verified
WOMAC pain −1.83 (9 mg) and −1.61 (12 mg) points vs placebo on a 0–10 scale at 68 weeks in TRIUMPH-4; −1.35, −1.61 and −1.77 (4/9/12 mg) at 80 weeks in TRIUMPH-1-OA (hybrid-treatment estimand). Weight −15.4 and −19.2 percentage points vs placebo in TRIUMPH-4 (treatment-regimen estimand).
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 9 mg week 68 | −4.0 | −2.1 | −1.8 (−2.4 to −1.3) points | verified |
| WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 9 mg week 68 | −3.6 | −1.8 | −1.8 (−2.4 to −1.3) points | verified |
| WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 12 mg week 68 | −3.7 | −2.1 | −1.6 (−2.2 to −1.1) points | verified |
| WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 12 mg week 68 | −3.6 | −1.8 | −1.8 (−2.3 to −1.2) points | verified |
| WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 4 mg week 80 | −3.2 | −1.9 | −1.4 (−1.9 to −0.8) points | verified |
| WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 4 mg week 80 | −3.2 | −1.5 | −1.7 (−2.2 to −1.1) points | verified |
| WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 9 mg week 80 | −3.5 | −1.9 | −1.6 (−2.2 to −1.0) points | verified |
| WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 9 mg week 80 | −3.4 | −1.5 | −1.9 (−2.5 to −1.3) points | verified |
| WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 12 mg week 80 | −3.6 | −1.9 | −1.8 (−2.3 to −1.2) points | verified |
| WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 12 mg week 80 | −3.5 | −1.5 | −1.9 (−2.5 to −1.4) points | verified |
Verbatim quotes (10)
- WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
was -3.96 with 9-mg, -3.74 with 12-mg retatrutide, and -2.12 with placebo (estimated treatment difference [ETD] vs. placebo [95% CI]: 9-mg: -1.83 [-2.37,-1.30];
- WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
Physical Function score (0.22) (0.22) Treatment comparison -1.83 (-2.40, - -1.77 (-2.34, - __
- WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
12-mg: -1.61 [-2.16,-1.07], all p<0.001; Table 2, Fig. 1)
- WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
-3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53
- WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
baseline to week 80 was -3.22 (4-mg) [key secondary endpoint], -3.48 (9-mg), and -3.64 (12- mg) and -1.87 (placebo) (ETD vs. placebo [95% CI]: 4-mg: -1.35 [-1.92,-0.78]; 9-mg: -1.61 [- 2.20,-1.02]; 12-mg: -1.77 [-2.34,-1.20]; all p<0.001; Table 2, Fig. 1)
- WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
-3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53
- WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
baseline to week 80 was -3.22 (4-mg) [key secondary endpoint], -3.48 (9-mg), and -3.64 (12- mg) and -1.87 (placebo) (ETD vs. placebo [95% CI]: 4-mg: -1.35 [-1.92,-0.78]; 9-mg: -1.61 [- 2.20,-1.02]; 12-mg: -1.77 [-2.34,-1.20]; all p<0.001; Table 2, Fig. 1)
- WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
-3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53
- WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
baseline to week 80 was -3.22 (4-mg) [key secondary endpoint], -3.48 (9-mg), and -3.64 (12- mg) and -1.87 (placebo) (ETD vs. placebo [95% CI]: 4-mg: -1.35 [-1.92,-0.78]; 9-mg: -1.61 [- 2.20,-1.02]; 12-mg: -1.77 [-2.34,-1.20]; all p<0.001; Table 2, Fig. 1)
- WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
-3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53
Related registry entries
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| TRIUMPH-4 / TRIUMPH-1-OA A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee | CV outcomes | Phase 3 | completed | 2023-08 → 2025-11 | 445 | Completed; results not yet public | NCT05931367 |
| TRIUMPH-1 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight | Obesity | Phase 3 | completed | 2023-07 → 2026-04 | 2335 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT05929066 |
Primary sources
- Schnitzer TJ, Hunter DJ, Conaghan PG, Sharma AM, Pedersen SD, Chen K, et al. Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity. N Engl J Med. 2026. PMID: 43001755.
- Eli Lilly and Company. A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-4). ClinicalTrials.gov identifier NCT05931367. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05931367
- ClinicalTrials.gov NCT05929066
How to cite this page
Medical Adviser's Group. Incretin Atlas: TRIUMPH-4 / TRIUMPH-1-OA. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-4-triumph-1-oa/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.